Shield Therapeutics (STU:1JS) Interest Expense: €-6.38 Mil (TTM As of Dec. 2025)


What is Shield Therapeutics Interest Expense?

Shield Therapeutics STU:1JS Interest Expense is €-6.38 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Shield Therapeutics's interest expense for the six months ended in Dec. 2025 was € -3.13 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-6.38 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Shield Therapeutics's Operating Income for the six months ended in Dec. 2025 was € -3.64 Mil. Shield Therapeutics's Interest Expense for the six months ended in Dec. 2025 was € -3.13 Mil. Shield Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Shield Therapeutics  (STU:1JS) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Shield Therapeutics's Interest Expense for the six months ended in Dec. 2025 was €-3.13 Mil. Its Operating Income for the six months ended in Dec. 2025 was €-3.64 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was €25.74 Mil.

Shield Therapeutics's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Shield Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Shield Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Interest Expense Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.38 -0.93 -3.70 -6.33

Shield Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -1.51 -2.15 -3.26 -3.13

Shield Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-6.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-6.38 Mil mean?
Shield Therapeutics (STU:1JS) has a Interest Expense of €-6.38 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Shield Therapeutics and its competitors.
Is Shield Therapeutics' Interest Expense too high?
Shield Therapeutics' current Interest Expense is €-6.38 Mil.
How does Shield Therapeutics' Interest Expense compare to ZTS and UTHR?
Shield Therapeutics' Interest Expense of €-6.38 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Interest Expense is €-6.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Interest Expense is €-6.38 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Interest Expense is €-6.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK1JS:Germany
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.